FDA Approves Leucovorin for Folate Deficiency, Not Autism | Medscape

The Food and Drug Administration (FDA) has approved the use of leucovorin, a decades-old drug, for a very specific and rare genetic condition – cerebral folate deficiency (CFD) linked to mutations in the FOLR1 gene. This approval, however, does not extend to broader use for autism, despite recent claims suggesting a wider benefit. The decision follows a period of public discussion fueled by statements from U.S. Health leaders about leucovorin’s potential in treating autism spectrum disorder.

Understanding Cerebral Folate Deficiency and the FOLR1 Gene

Cerebral folate deficiency (CFD) is a neurological condition where folate, a B vitamin crucial for brain development, struggles to cross the blood-brain barrier. This deficiency can lead to a range of symptoms, including seizures, motor skill difficulties, and intellectual disability. We find several causes of CFD, including autoantibodies that block the folate receptor. The newly approved use of leucovorin targets a particularly rare form of CFD caused by a variant in the folate receptor 1 (FOLR1) gene – FOLR1-related cerebral folate transport deficiency (FOLR1-CFTD). According to a senior FDA official, this specific genetic form affects less than 1 in a million people. Fierce Pharma reports that the FDA approved GSK’s Wellcovorin for this specific subset.

The Shift in Perspective: From Broad Autism Treatment to Targeted Genetic Condition

The FDA’s current decision represents a narrowing of scope from earlier suggestions regarding leucovorin’s application. In September 2025, FDA Commissioner Marty Makary, M.D., indicated that leucovorin could potentially benefit “hundreds of thousands of kids” with autism, citing a study where he claimed “two-thirds of kids with autism symptoms had improvement and some marked improvement” after receiving the drug. The Washington Post details this shift. However, the FDA is now clarifying that the evidence does not support a broader approval for autism itself. The agency is approving the drug for a very specific, genetically defined condition that *can* occur in some individuals with autism, but is not representative of the condition as a whole.

Robert F. Kennedy Jr.’s Role and the FDA’s Response

The increased attention surrounding leucovorin stemmed in part from comments made by U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. In a White House press conference approximately five months ago, Kennedy touted leucovorin as “an exciting therapy that may benefit large numbers of children who suffer from autism.” This prompted significant public interest and discussion. The FDA’s recent actions can be seen, in part, as a response to these earlier statements, and a move to clarify the drug’s approved use. Politico reports that the FDA is backing away from Kennedy Jr.’s earlier claims.

What Does This Mean for Individuals with Autism?

It’s crucial to understand that this FDA approval does *not* mean leucovorin is now a recommended treatment for autism. The drug is specifically approved for individuals with CFD-FOLR1, a very rare genetic condition. While some individuals with autism may also have CFD-FOLR1, What we have is not the case for the vast majority. The FDA emphasizes that leucovorin “is not a cure for autism,” but acknowledges there is some evidence it may be helpful for those with the specific genetic deficiency.

For families seeking information about potential treatments for autism, it remains essential to consult with qualified healthcare professionals and rely on evidence-based therapies. The Autism Speaks website (https://www.autismspeaks.org/) provides comprehensive information about autism spectrum disorder, including diagnosis, treatment options, and support resources.

The Importance of Genetic Testing and Accurate Diagnosis

The FDA’s approval highlights the importance of accurate genetic testing in identifying individuals who may benefit from this targeted treatment. The approval is contingent on confirmation of a variant in the FOLR1 gene. This underscores the growing role of precision medicine – tailoring medical treatment to the individual characteristics of each patient, including their genetic makeup. Without confirmation of the FOLR1 mutation, leucovorin is not indicated.

Trial Absence and Future Research

Notably, the FDA approved leucovorin for this rare condition without requiring a traditional clinical trial. This decision was based on existing scientific literature and a thorough review of the available data. However, it also means that further research is needed to fully understand the long-term effects and optimal dosage of leucovorin in individuals with CFD-FOLR1. Ongoing surveillance and data collection will be crucial to monitor the drug’s effectiveness and safety in this patient population.

Looking Ahead: Continued Evaluation and Data Gathering

The FDA’s process doesn’t end with approval. The agency will continue to monitor the use of Wellcovorin through post-market surveillance, gathering data on its real-world effectiveness and any potential adverse effects. This ongoing evaluation is standard practice for newly approved drugs, particularly those approved without extensive clinical trials. Further studies may be conducted to refine treatment protocols and expand our understanding of CFD-FOLR1 and the role of leucovorin in managing this rare condition. Individuals and healthcare providers are encouraged to report any adverse events to the FDA’s MedWatch program.